Author:
Campo R.,DeJesus E.,Bredeek U. F.,Henry K.,Khanlou H.,Logue K.,Brinson C.,Benson P.,Dau L.,Wang H.,White K.,Flaherty J.,Fralich T.,Guyer B.,Piontkowsky D.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)
Reference22 articles.
1. Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study [oral presentation];Martinez,2007
2. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy;Sax;N Engl J Med,2009
3. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients;Valantin;J Antimicrob Chemother,2010
4. Switching from kivexa [ABC/3TC ]+kaletra [LPV/r] to truvada [TDF/FTC]+kaletra [LPV/r] reduces high hholesterol: results of a 12 week randomized, controlled study (ROCKET II) [Poster WEPE0110];Behrens,2010
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献